Novo to cut GLP-1 drug prices; Palvella soars on study data

Wegovy and Ozempic’s list prices will be reduced by as much as 50% effective next year. Elsewhere, Palvella’s market value surged past $1 billion while Pfizer nabbed rights to another obesity drug.

Source link